Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration

A method of treating a patient with brain injury or suspected of having brain injury, the method comprising:

• (a) administering over time a drug or drug treatment comprising a single dose or multiple doses of the drug to the patient;
• (b) detecting at least two citrullinated biomarker proteins selected from the group consisting of citrullinated neurogranin (cit-NRGN), citrullinated glial fibrillary acidic protein (cit-GFAP), and citrullinated myelin basic protein (cit-MBP) in biological samples of the patient obtained at (i) a first time point and (ii) at least one second time point following the first time point;
• (c) measuring levels of the at least two citrullinated biomarker proteins detected at the at least one second time point that trend toward normal levels of the same biomarker proteins in a non-brain injury or healthy control compared to the measured levels of the at least two citrullinated biomarker proteins detected at the first time point;
• and
• (d) discontinuing administering the drug or drug treatment to the patient subsequent to the detecting and measuring steps (b) and (c).